Kodak Oncology Imaging Film System Wins R&D 100 Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

ROCHESTER, NY-The Eastman Kodak Company has been selected to receive the 1997 R&D 100 Award for its development of the Kodak EC-L film system for oncology imaging. The award-winning system provides high-contrast images for use in monitoring radiation treatment of cancer patients.

ROCHESTER, NY—The Eastman Kodak Company has been selected to receive the 1997 R&D 100 Award for its development of the Kodak EC-L film system for oncology imaging. The award-winning system provides high-contrast images for use in monitoring radiation treatment of cancer patients.

The award has been sponsored by R&D Magazine for 35 years. Sometimes referred to as “the Nobel Prize of applied research,” the R&D 100 Award pays tribute to products and processes that have revolutionized their particular field and impacted the way people live. Past winners, for example, have included the automated teller machine, the fax machine, the digital wristwatch, and antilock brakes.

The EC-L film system has advanced the precision of radiation therapy by allowing oncologists to verify treatment of tumors with increased ease and accuracy, the company said. The complete Kodak EC-L film system consists of Kodak EC-L film and Kodak EC-L oncology cassettes.

The EC-L film system combines fluorescent intensifying screens and a low-speed, very-fine-grain, high-contrast film emulsion. According to Kodak, the resulting images have significantly higher contrast—approximately four times that of conventional film systems—and show more anatomic detail (see images in the figure ).

The system was developed by three scientists in Kodak’s Health Imaging Division (see photograph ): Arthur G. Haus, director of medical physics;

Kenneth E. Huff, senior research physicist; and Robert E. Dickerson, senior technical associate for the Film Development Laboratory.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content